Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
Corcept Therapeutics (NASDAQ: CORT) will report its second quarter financial results and provide a corporate update on August 3, 2022, with a conference call at 5:00 p.m. ET. The company has a robust portfolio of proprietary compounds targeting cortisol modulation for severe disorders, including Cushing’s syndrome and cancers. They are also working on clinical trials for other conditions. The call will be accessible through registration, and a replay will be available on their website.
- Strong pipeline of proprietary cortisol-modulating compounds.
- Ongoing clinical trials for treatments of serious disorders.
- None.
MENLO PARK, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on August 3, 2022. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Conference Call Information
Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number, and a unique access PIN. Each access PIN will accommodate one caller.
Additionally, a listen-only webcast will be available by clicking here.
A replay of the call will be available on the Investors / Events tab of www.corcept.com.
About Corcept Therapeutics
Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. The company is conducting clinical trials of its leading cortisol modulators as potential treatments for patients with Cushing’s syndrome, ovarian, adrenal and prostate cancer, weight gain caused by the use of antipsychotic medications and liver disease. Corcept’s drug Korlym® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome.
CONTACT:
Corcept Therapeutics
Investor Relations
ir@corcept.com
www.corcept.com
FAQ
When will Corcept Therapeutics report its second quarter financial results?
What time is the conference call for Corcept Therapeutics?
How can I listen to the Corcept Therapeutics conference call?
What is the focus of Corcept Therapeutics' clinical trials?
